[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis

• Conditions: joint inflammation in skin disease psoriasis; psoriatic arthritis; 10023213; 10014982

• Registration Number: NL-OMON56612
• Lead Sponsor: Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

- Psoriasis
- >=1 arthralgia and/or enthesiopathy in >=1 location(s) <= 1 year;
- And >=1 of the following;
- Nail psoriasis
- First-degree relative with PsA
- BSA >=3%

Exclusion Criteria

- Other rheumatic disease (such as Axial SpA, RA, SLE, Sjögren)
- Osteoarthritis and/or mechanical explanation of the pain in joints and/or
tendons
- Clinically evident arthritis (and/or tenosynovitis)
- Systemic therapy for psoriasis (DMARD, bDMARD)
- Treatment with study medication in the past 3 months
- Pregnancy or breast-feeding

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint(s)/parameter(s) are the number of individuals with<br /><br>PET-positive lesions, the distribution of PET-positive lesions and the<br /><br>quantitative [18F]Fluoride uptake in PET-positive lesions. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome is the correlation between PET outcome and development of PsA<br /><br>in 2 years follow up.</p><br>